hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06373952, orgStudyIdInfo id: 23-08-658-910, briefTitle: Integrated Online-to-offline (O2O) Model of Care for HIV Prevention and Treatment Among Men Who Have Sex With Men, acronym: CINTAI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-19, primaryCompletionDateStruct date: 2025-01-06, completionDateStruct date: 2025-02-18, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: University of Connecticut, class: OTHER, collaborators name: University of Malaya, descriptionModule briefSummary: The proposed research focuses on developing and testing a web-based platform, called Jom-TestPlus, that will incorporate HIV self-testing (HIVST) with real-time e-counseling (eHIVST) with online-to-offline (O2O) linkage to HIV prevention and treatment services while simultaneously co-addressing chemsex-related needs for men who have sex with men (MSM) in Malaysia. This model represents a potentially impactful strategy for reaching marginalized populations, like MSM, and allows immediate engagement in the post-test linkage process to prevention or treatment services., conditionsModule conditions: HIV Prevention Program, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 78, type: ESTIMATED, armsInterventionsModule interventions name: Online to offline counseling, outcomesModule primaryOutcomes measure: HIVST uptake, primaryOutcomes measure: Linkage to PrEP, primaryOutcomes measure: Linkage to HIV treatment services, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centre of Excellence For Research in AIDS (CERiA), city: Kuala Lumpur, country: Malaysia, geoPoint lat: 3.1412, lon: 101.68653, hasResults: False
protocolSection identificationModule nctId: NCT06373939, orgStudyIdInfo id: Pneumoscope study, briefTitle: Performance and Safety of the Pneumoscope Device in Adults and Children, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Pediatric Clinical Research Platform, class: OTHER, collaborators name: University Hospital, Geneva, descriptionModule briefSummary: Respiratory diseases are associated with high morbidity and mortality worldwide. Proper diagnosis and risk assessment of these conditions are essential for optimal management. Clinicians use three particularly useful tools to identify these conditions when assessing the patient's status: the stethoscope, the pulse oximeter, and the thermometer. The Pneumoscope is an all-in-one device including a digital stethoscope, a pulse oximeter, and a thermometer. This study aims to assess the performance and safety of the Pneumoscope in recording respiratory sounds, body temperature, non-invasive blood oxygen saturation levels and heart rate in children and adults., conditionsModule conditions: Respiratory Diseases, conditions: Pneumonia, conditions: Asthma, conditions: Cyanotic Heart Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This single center, open, non-controlled investigation will be conducted at one site; the University Hospitals of Geneva, Switzerland. This will be a non-inferiority study between Pneumoscope and CE marked comparable medical devices in children and adults., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 225, type: ESTIMATED, armsInterventionsModule interventions name: Digital lung auscultation, interventions name: Pulse oximetry measurement, interventions name: Non invasive body temperature measurement, outcomesModule primaryOutcomes measure: Evaluation of Pneumoscope's built-in sensors, secondaryOutcomes measure: Collect audio records of lung sounds for AI models training and sensor calibration, secondaryOutcomes measure: Pulse oximetry, secondaryOutcomes measure: Body temperature, eligibilityModule sex: ALL, minimumAge: 1 Year, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Geneva University Hospitals, city: Geneva, zip: 1205, country: Switzerland, contacts name: Alain Gervaix, Prof, role: CONTACT, phone: (0)22 372 45 55, phoneExt: +41, email: Alain.Gervaix@hcuge.ch, contacts name: Johan Siebert, MD, role: CONTACT, phone: (0)79 553 40 72, phoneExt: +41, email: Johan.Siebert@hcuge.ch, contacts name: Johan N Siebert, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Laurence Lacroix-Duccardonnoy, MD, role: SUB_INVESTIGATOR, contacts name: Isabelle Ruchonnet-Métrailler, MD, role: SUB_INVESTIGATOR, geoPoint lat: 46.20222, lon: 6.14569, hasResults: False
protocolSection identificationModule nctId: NCT06373926, orgStudyIdInfo id: PI2019_843_0010, briefTitle: Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome, acronym: MONOCYTAN, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-28, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire, Amiens, class: OTHER, descriptionModule briefSummary: Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator, plays a pivotal role in regulation of fibrinolysis in vitro and in vivo and has been identified as a new autoantigen in antiphospholipid syndrome (APS). ANXA2 can exist as a monomer or a heterotetrameric complex with S100A10 protein. The aim of this study was to evaluate the cell membrane expression of ANXA2 on circulating monocytes in APS by flow cytometry. Several pathogenic mechanisms are involved in APS such as activation of endothelial cells, platelets and monocytes, inhibition of the natural anticoagulant protein C/protein S pathway, activation of the complement system and also impairment of fibrinolysis. Annexin A2 which hits binding partner S100A10, ANXA2 forms a cell surface complex that regulates generation of plasmin. ANXA2 is involved in the pathogenesis of APS-associated through several possible mechanisms. Human peripheral blood monocytes represent the major circulating ANXA2-expressing cell and ANXA2-mediated assembly of plasminogen and tissue activator of plasminogen (tPA) on monocyte/macrophages contributes to plasmin generation. Thus the investigators could suppose that decrease of cell membrane expression of ANXA2 on circulating monocytes represent a new pathogenic mechanism in APS., conditionsModule conditions: Antiphospholipid Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: blood withdrawal, outcomesModule primaryOutcomes measure: Cell membrane expression rate of ANXA2 on circulating monocytes in APS, secondaryOutcomes measure: Cellular expression of ANXA2 and S100A10 in APS patients, secondaryOutcomes measure: cell membrane expression of ANXA2 and S100A10 in APS patients, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU Amiens, status: RECRUITING, city: Amiens, zip: 80054, country: France, contacts name: Valéry SALLE, MD, role: CONTACT, phone: +33 3 22 66 82 30, email: salle.valery@chu-amiens.fr, geoPoint lat: 49.9, lon: 2.3, hasResults: False
protocolSection identificationModule nctId: NCT06373913, orgStudyIdInfo id: MASP2NSRZL, briefTitle: The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom, acronym: PCSK9, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2027-07-30, completionDateStruct date: 2028-07-30, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Kolding Sygehus, class: OTHER, collaborators name: Odense University Hospital, collaborators name: Vejle Hospital, descriptionModule briefSummary: Nephrotic syndrome (NS) is characterized by gross proteinuria (\>3.5 g/day), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality.The study aim is to investigate the role of the protein convertase subtilisin/kexin type 9 (PCSK9) in hyperlipidemia of NS, which has been suggested to play an important role. This is done by testing the following hypotheses:1. PCSK9 is increased in patients with NS and hyperlipidemia compared to kidney-healthy controls2. The level of PCSK9 in plasma correlates to the degree of proteinuria.3. PCSK9 i increased in the kidney tissue of patients with NSThe study will compare plasma levels of PCSK9 in correlation with degree of protein in the urine between test persons with NS and kidney healthy controls. Furthermore the investigators will study the the degree of PCSK9 in the kidney in biopsies obtained from test persons with nephrotic syndrome and test persons without proteinuria., conditionsModule conditions: Hyperlipidemias, conditions: Nephrotic Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Plasma PCSK9 correlated to the degree of protein in the urine, primaryOutcomes measure: Degree of PCSK9 in kidney tissue, secondaryOutcomes measure: Localization of PCSK9 in kidney tissue, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kolding Sygehus, Lillebælt Hospital, status: RECRUITING, city: Kolding, zip: 6000, country: Denmark, contacts name: Rikke Z Langkilde, md, phd, role: CONTACT, phone: 004576362554, contacts name: Anne D Thuesen, md, phd, role: CONTACT, phone: 004576360555, email: Anne.Daugaard.Thuesen2@rsyd.dk, geoPoint lat: 55.4904, lon: 9.47216, hasResults: False
protocolSection identificationModule nctId: NCT06373900, orgStudyIdInfo id: IndusH, briefTitle: Wound Closure After Total Knee Arthroplasty: Comparison of Polypropylene and Polyglactin 910 Suture., statusModule overallStatus: COMPLETED, startDateStruct date: 2022-02-13, primaryCompletionDateStruct date: 2022-02-19, completionDateStruct date: 2022-03-30, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Indus Hospital and Health Network, class: OTHER, descriptionModule briefSummary: Comparison of wound complication and scar formation in patient undergone bilateral total knee replacement comparison between polypropylene and polyglactin 910 suture. patient randomised according to SNOS protocol into group A and B for their right and left knee closure with each suture. patient followed on 3rd, 7th, 15th and 30th post operative day for wound healing, wound dehiscence and scar formation., conditionsModule conditions: Wound Heal, conditions: Wound Dehiscence, conditions: Wound Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: SINGLE, maskingDescription: SNOS protocol, whoMasked: PARTICIPANT, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: wound closure, outcomesModule primaryOutcomes measure: Wound characteristics and complications, primaryOutcomes measure: Wound Infection Grade, primaryOutcomes measure: Hollander Cosmetic Wound Evaluation Score, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Indus Hospital and Health Network, city: Karachi, state: Sindh, zip: 74900, country: Pakistan, geoPoint lat: 24.8608, lon: 67.0104, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP_ICF, hasProtocol: True, hasSap: True, hasIcf: True, label: Study Protocol, Statistical Analysis Plan, and Informed Consent Form, date: 2022-02-04, uploadDate: 2024-04-03T02:55, filename: Prot_SAP_ICF_000.pdf, size: 130365, hasResults: False
protocolSection identificationModule nctId: NCT06373874, orgStudyIdInfo id: MCBU-SBF-YC-04, briefTitle: The Effect of High Reality Simulation Environment on the Skills of Midwifery Students, in Newborn Heel Blood Collection, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2023-05-30, completionDateStruct date: 2023-05-30, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Celal Bayar University, class: OTHER, descriptionModule briefSummary: The researchers gave midwifery students theoretical training on how to take heel blood on a newborn model. Students were asked to take heel blood on the model in the high-reality simulation environment and simulation room. The student's ability to take heel blood before and after taking heel blood in a high-reality simulation environment or on a newborn model in a simulation environment, satisfaction with learning, anxiety and self-efficacy levels were compared., conditionsModule conditions: Students, conditions: Educational Problems, conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Parallel Assignment experimental study with experimental and control group, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 92, type: ACTUAL, armsInterventionsModule interventions name: Heel blood collection in a newborn simulation model, outcomesModule primaryOutcomes measure: Skill checklist, primaryOutcomes measure: State and Trait Anxiety Scales, primaryOutcomes measure: Self-Efficacy Scale, primaryOutcomes measure: Student Satisfaction and Self-Confidence in Learning Questionnaire, eligibilityModule sex: FEMALE, minimumAge: 21 Years, maximumAge: 32 Years, stdAges: ADULT, contactsLocationsModule locations facility: Manisa Celal Bayar University Faculty of Health Sciences, Department of Midwifery, city: Manisa, zip: 45140, country: Turkey, geoPoint lat: 38.61202, lon: 27.42647, locations facility: Yonca çiçek okuyan, city: Manisa, zip: 45140, country: Turkey, geoPoint lat: 38.61202, lon: 27.42647, hasResults: False
protocolSection identificationModule nctId: NCT06373861, orgStudyIdInfo id: 20-0482, briefTitle: Generating Advancements Through Longitudinal Analysis in X and Y Variations (GALAXY), acronym: GALAXY, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-04-28, primaryCompletionDateStruct date: 2037-04, completionDateStruct date: 2037-04, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: University of Colorado, Denver, class: OTHER, collaborators name: Children's Hospital Colorado, descriptionModule briefSummary: GALAXY is a registry research study that plans to learn more about individuals with X\&Y variations (also called sex chromosome aneuploidies) through collecting information from medical records.This includes genetic tests, imaging, medications, and more for hundreds of patients seen at a number of clinics across the US. The purpose of the GALAXY Registry is to collect and store this information with the overall goal to improve health outcomes in individuals with X\&Y variations and the care they receive., conditionsModule conditions: Sex Chromosome Aneuploidy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 5000, type: ESTIMATED, armsInterventionsModule interventions name: no intervention, outcomesModule primaryOutcomes measure: Health Conditions, secondaryOutcomes measure: Prevalence of mental health diagnoses, secondaryOutcomes measure: Cardiometabolic diagnoses - prevalence of obesity, secondaryOutcomes measure: Cardiometabolic diagnoses - prevalence of dyslipidemia, secondaryOutcomes measure: Cardiometabolic diagnoses-prevalence of hypertension, secondaryOutcomes measure: Autoimmune diagnoses - prevalence of hypothyroidism and of hyperthyroidism, secondaryOutcomes measure: Autoimmune diagnoses - prevalence of diabetes, eligibilityModule sex: ALL, minimumAge: 0 Days, maximumAge: 100 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Children's Hospital Colorado, status: RECRUITING, city: Aurora, state: Colorado, zip: 80045, country: United States, contacts name: Shanlee M Davis, MD, PhD, role: CONTACT, phone: 720-777-6073, email: shanlee.davis@childrenscolorado.org, geoPoint lat: 39.72943, lon: -104.83192, hasResults: False
protocolSection identificationModule nctId: NCT06373848, orgStudyIdInfo id: 346, briefTitle: Comparison of Salivary Parameters in Patients Receiving CoQ10 and Vitamin E Supplementation, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2024-08-20, completionDateStruct date: 2024-09-15, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Islamic Azad University, Tehran, class: OTHER, descriptionModule briefSummary: Comparison of salivary markers in patients with Initial chronic periodontitis after non-surgical periodontal treatment with CoQ10 supplementation with vitamin E, conditionsModule conditions: Periodontal Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Parallel Assignment, Randomized, Double-blind, Controlled design., primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: The study was carried out utilizing a double-blind approach. In order to guarantee objectivity, all three groups - the Vitamin E group, the Coq10 group, and the control group - received medications that were indistinguishable in terms of appearance, packaging, and color. Additionally, to minimize any potential bias, a clinician who had no association with the research labeled the medications as A, B, and C (empty) based on their content, and then distributed them among the patients., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 85, type: ESTIMATED, armsInterventionsModule interventions name: Receive 30 mg of Coq10, outcomesModule primaryOutcomes measure: Total Antioxidant capacity (TAC) of saliva, secondaryOutcomes measure: Bleeding on probing, eligibilityModule sex: ALL, minimumAge: 28 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Amirhossein Farahmand, city: Tehran, zip: 1947833113, country: Iran, Islamic Republic of, geoPoint lat: 35.69439, lon: 51.42151, hasResults: False
protocolSection identificationModule nctId: NCT06373835, orgStudyIdInfo id: EMODEPSIDE_LAOS, briefTitle: Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Swiss Tropical & Public Health Institute, class: OTHER, collaborators name: National Institute of Public Health, Vientiane, Laos, descriptionModule briefSummary: Efficacy, safety and pharmacokinetics of ascending dosages of emodepside and in comparison to ivermectin against Strongyloidiasis stercoralis in adults: randomized stage II seamless adaptive controlled trials, conditionsModule conditions: Strongyloides Stercoralis Infection, conditions: Strongyloidiasis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: Emodepside, outcomesModule primaryOutcomes measure: Cure rate (CR) of emodepside against Strongyloides stercoralis, secondaryOutcomes measure: Safety and tolerability of the dose-dependent emodepside treatment regimes, and compared with ivermectin., secondaryOutcomes measure: Geometric Mean Larvae Reduction Rate (LRR) of emodepside against Strongyloides stercoralis., secondaryOutcomes measure: Exposure response of emodepside in adults, secondaryOutcomes measure: Cure rate (CR) and egg reduction rate (ERR) with other soil-transmitted helminths (STH) and trematodes, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06373822, orgStudyIdInfo id: 2024/18JAN/028, briefTitle: New Perspectives in Adenomyosis Pathogenesis With Epigenetic Analysis and miRNAs, acronym: ADENO-MIRNA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-21, primaryCompletionDateStruct date: 2031-09, completionDateStruct date: 2031-09, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Université Catholique de Louvain, class: OTHER, descriptionModule briefSummary: Objectives:To identify differentially expressed miRNAs in the blood of adenomyosis patients in view to develop new diagnostic methodsHypotheses Circulating miRNAs may be abnormally expressed in patients suffering from adenomyosis and could be used to diagnose the diseaseStudy Design Blood samples will be collected from healthy subjects and adenomyosis patients and miRNAs will be isolated and analyzed to detect potential differences., conditionsModule conditions: Adenomyosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Circulating-mirna, outcomesModule primaryOutcomes measure: Circulating-miRNA as diagnostic biomarkers, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CUSL, status: RECRUITING, city: Brussel, state: Woluwe-Saint-Lambert, zip: 1200, country: Belgium, contacts name: Emilie Wacheul, MD, role: CONTACT, phone: 027645246, email: emilie.wacheul@uclouvain.be, geoPoint lat: 50.85045, lon: 4.34878, hasResults: False